This is a working overview of Melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
=== Economics === Pregabalin is available as a generic medication in a number of countries, including the United States as of July 2019. In the United States as of July 2019 the wholesale/pharmacy cost for generic pregabalin is $0.17–0.22 per 150-mg capsule. From 2008 until 2018, Pfizer engaged in extensive direct-to-consumer advertising campaigns to promote its branded product Lyrica for fibromyalgia and diabetic nerve pain indications. In January 2016, the company spent a record amount, $24.6 million for a single drug on TV ads, reaching global revenues of $14 billion, more than half in the United States. Up until 2009, Pfizer promoted Lyrica for other uses that had not been approved by medical regulators. For Lyrica and three other drugs, Pfizer was fined a record amount of $2.3 billion by the Department of Justice, after pleading guilty to advertising and branding "with the intent to defraud or mislead". Pfizer illegally promoted the drugs, with doctors "invited to consultant meetings, many in resort locations; attendees expenses were paid; they received a fee just for being there", according to prosecutor Michael Loucks.
==== Mexico ==== In October 2020, Deputy Secretary of Prevention and Health Promotion Hugo López-Gatell Ramírez stated at a news conference that Mexico would not necessarily follow the United States in approving the drug for use in Mexico. López-Gatell explained that the Federal Commission for the Protection against Sanitary Risk (Cofepris) had already twice denied the approval of remdesivir because, in that agency's view, the evidence does not suggest "sufficient efficacy". In March 2020, Cofepris authorized the drug for emergency cases, advising continuous surveillance of the integral health of the patient.
Pyruvate:ferredoxin oxidoreductase, which converts pyruvate into acetyl-CoA and CO2 while reducing the ferredoxin. Hydrogenase, which converts H+ into H2 while oxidizing the ferredoxin. Acetyl-CoA synthetase (in reverse), which converts acetyl-CoA and ADP + Pi into acetate, coenzyme A, and ATP. (A variant of the reaction uses acetate:succinate CoA transferase and succinyl-CoA synthatase in reverse.) The net reaction is conversion of singular equivalents of pyruvate, ADP, and Pi into ATP, CO2, acetate, and H2.
=== Controls === Hydraulically driven. An SAU-1T-2 automatic flight control system offers assisted manual or automatic flight, with no manual option. Four independent hydraulic systems power all flight controls and the built-in airstairs. Fluid is to the NGZh, rather than AMG, formula.
Sources: en.wikipedia.org
=== Mosquitoes === Methods of resistance include thickening of the cuticle of the insect to limit permeation of the insecticide, metabolic resistance via overexpression of metabolizing cytochrome P450 mono-oxygenases and glutathione-S-transferases, and the knockdown resistance (kdr) sodium channel mutations which render the action of insecticides ineffectual, even when co-administered with piperonyl butoxide. Characterization of the different forms of resistance among mosquitoes has become a top priority in groups studying tropical medicine due to the high mortality of those who reside in endemic areas.
The process of RNAi was referred to as "co-suppression" and "quelling" when observed prior to the knowledge of an RNA-related mechanism. The discovery of RNAi was preceded first by observations of transcriptional inhibition by antisense RNA expressed in transgenic plants, and more directly by reports of unexpected outcomes in experiments performed by plant scientists in the United States and the Netherlands in the early 1990s. In an attempt to alter flower colors in petunias, researchers introduced additional copies of a gene encoding chalcone synthase, a key enzyme for flower pigmentation into petunia plants of normally pink or violet flower color. The overexpressed gene was expected to result in darker flowers, but instead caused some flowers to have less visible purple pigment, sometimes in variegated patterns, indicating that the activity of chalcone synthase had been substantially decreased or became suppressed in a context-specific manner. Another early observation of RNAi came from a study of the fungus Neurospora crassa, although it was not immediately recognized as related. Further investigation of the phenomenon in plants indicated that the downregulation was due to post-transcriptional inhibition of gene expression via an increased rate of mRNA degradation. This phenomenon was called co-suppression of gene expression, but the molecular mechanism remained unknown. Not long after, plant virologists working on improving plant resistance to viral diseases observed a similar unexpected phenomenon.
== Partitioning and transmutation strategy == Many efforts are being devoted to develop an advanced reprocessing approach with the aim to further reduce the radiotoxicity inventory of the spent nuclear fuel by removing all minor actinides (Neptunium, Americium and Curium) and the long-lived fission products (LLFP) from the high active raffinate downstream of the PUREX process. Before the conditioning process, the long-lived radionuclides undergo a transmutation into short-lived or stable nuclides by nuclear reactions. This coupled approach is known as Partitioning and Transmutation strategy (P&T), which inclusion in an advanced closed fuel cycle could lead to strongly reduce long-term radiotoxicity, volume and decay heat of the final waste thus simplifying a performance assessment of a future nuclear waste repository and enhancing proliferation resistance criteria. Two potential process options for the partitioning of spent nuclear fuel are being developed: hydrometallurgical and pyrometallurgical processes. The hydrometallurgical partitioning, also known as solvent extraction process, was born and developed in Europe thereby becoming the reference technology for future SNF reprocessing at industrial level, whereas the pyrometallurgical option started in the United States and Russia as an alternative to the aqueous processes.
Sources: en.wikipedia.org
However, temperatures at Plateau Station were only recorded during the 37 months that it was active. Had a lower temperature than the Vostok record occurred there at a later date, it would never have been recorded. Monitoring stations in Antarctica are few and far between; prior to 1995, Vostok was the only research station on the Antarctic Plateau above the elevation of 3,000 m (with the exception of Plateau Station during the brief period that it was active in the 1960s), with no other stations for several hundred kilometers in any direction. Temperatures below −89.2 °C (−128.6 °F), if they did occur elsewhere, would not have been recorded. The automatic weather station at Dome A was only installed in 2005, and has recorded −82.5 °C (−116.5 °F) as the coldest so far (2010). However, a review of satellite measurements taken between 2010 and 2013 found several places located along a ridge between Dome A and Dome F which recorded even lower temperatures of −92 to −94 °C (−134 to −137 °F), with the lowest reliable temperature being −93.2 °C (−135.8 °F) recorded in 2010, at 81°48′S 59°18′E, at an elevation of 3,900 m (12,800 ft). The extreme low temperatures are found in hollows slightly below the peak of the ice ridge, where cold air gets trapped as it flows downhill, and since the same low temperature ranges were detected at several different sites along the ridge across multiple years, it is thought this may be the lowest temperature achievable under local atmospheric conditions.
=== 2026 recalls of Semaglutide === In mid August 2026, Dr. Reddy's Laboratories Canada Inc. issued a class 2 recall on its Semaglutide Injection due to affected lots containing a 4 mg pen but is labelled as a 2 mg pen.
== History == In 1799, British chemist Charles Hatchett experimented with decalcifying the shells of various crustaceans, finding that a soft, yellow and cartilage-like substance was left behind that is now known to be chitin. In 1859, French physiologist Charles Marie Benjamin Rouget found that boiling chitin in potassium hydroxide solution could deacetylate it to produce a substance that was soluble in dilute organic acids, that he called chitine modifiée. In 1894, German chemist Felix Hoppe-Seyler named the substance chitosan. From 1894 to 1930 there was a period of debate and confusion over the exact composition of chitin and particularly whether animal and fungal forms were the same chemicals. In 1930 the first chitosan films and fibres were patented but competition from petroleum-derived polymers limited their uptake. It was not until the 1970s that there was renewed interest in the compound, spurred partly by laws that prevented the dumping of untreated shellfish waste.
== Plot == The West Berlin office of MI6, under station chief Alec Leamas, has suffered from reduced effectiveness. He is recalled to London shortly after the death of one of his operatives and is seemingly drummed out of the agency. In reality, a carefully staged transformation of Leamas has been arranged by Control, the agency's chief. Appearing to be depressed, embittered and alcoholic, Leamas takes work as an assistant at a local library. There he begins a relationship with his colleague Nan Perry, a young and idealistic member of the British Communist Party. Leamas spends most of his small salary on alcohol, leaving him constantly low on funds. He drunkenly assaults a shopkeeper who refuses him credit and is briefly jailed. His predicament attracts the attention of the East German Intelligence Service, which sees him as a potential defector. Leamas is approached by a series of operatives, each one passing him up the chain of the East German intelligence service, and he expresses a willingness to sell British secrets for money. He eventually flies to the Netherlands to meet an agent named Peters, who decides that his information is important enough to send him on to East Germany. At a German country house, Leamas is introduced to Jens Fiedler, who becomes his main interrogator. Leamas then begins to carry out his secret mission, which is to share information that suggests a high-ranking East German intelligence officer named Mundt is a paid informant of the British.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.